{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:12:09Z","timestamp":1780053129432,"version":"3.54.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013631","name":"Montana Water Center, Montana State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013631","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","award":["46.104"],"award-info":[{"award-number":["46.104"]}],"id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","award":["164.514"],"award-info":[{"award-number":["164.514"]}],"id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.clinthera.2024.12.006","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T19:16:43Z","timestamp":1736018203000},"page":"189-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Health Care Resource Use and Medical Costs Among Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine Nasal Spray or Traditional Treatments in the United States"],"prefix":"10.1016","volume":"47","author":[{"given":"Lisa","family":"Harding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryia","family":"Zhdanava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Teeple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Porpong","family":"Boonmak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kruti","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.12.006_bib0001","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2022 national survey on drug use and health. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt42731\/2022-nsduh-nnr.pdf. Accessed March 12, 2024."},{"key":"10.1016\/j.clinthera.2024.12.006_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.690130","article-title":"Prevalence of suicidality in major depressive disorder: a systematic review and meta-analysis of comparative studies","volume":"12","author":"Cai","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0003","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/070674371405900303","article-title":"Suicidal behaviour in mood disorders\u2013who, when, and why?","volume":"59","author":"Isomets\u00e4","year":"2014","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0004","unstructured":"Substance Abuse and Mental Health Services Administration. Results from the 2020 National Survey on Drug Use and Health: detailed tables. Appendix B: list of tables. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt35323\/NSDUHDetailedTabs2020\/NSDUHDetailedTabs2020\/NSDUHDetTabsAppB2020.htm. Accessed March 12, 2024."},{"key":"10.1016\/j.clinthera.2024.12.006_bib0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/NDT.S229530","article-title":"The health-related quality of life, work productivity, healthcare resource utilization, and economic burden associated with levels of suicidal ideation among patients self-reporting moderately severe or severe major depressive disorder in a national survey","volume":"17","author":"Benson","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0006","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3109\/09638237.2014.928402","article-title":"The burden of living with and caring for a suicidal family member","volume":"23","author":"McLaughlin","year":"2014","journal-title":"J Ment Health"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0007","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jad.2022.05.086","article-title":"Excess healthcare resource utilization and healthcare costs among privately and publicly insured patients with major depressive disorder and acute suicidal ideation or behavior in the United States","volume":"311","author":"Zhdanava","year":"2022","journal-title":"J Affect Disord"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0008","series-title":"The American Psychiatric Association practice guideline for the treatment of patients with major depressive disorder, third edition","first-page":"1","author":"Gelenberg","year":"2010"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0009","series-title":"The American Psychiatric Association practice guideline for the assessment and treatment of patients with suicidal behaviors","first-page":"1","author":"Jacobs","year":"2010"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0010","unstructured":"Johnson & Johnson. Janssen announces U.S. FDA approval of SPRAVATO\u00ae (esketamine) CIII nasal spray to treat depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. https:\/\/www.jnj.com\/media-center\/press-releases\/janssen-announces-u-s-fda-approval-of-spravato-esketamine-ciii-nasal-spray-to-treat-depressive-symptoms-in-adults-with-major-depressive-disorder-with-acute-suicidal-ideation-or-behavior. Accessed August 3, 2020."},{"key":"10.1016\/j.clinthera.2024.12.006_bib0011","unstructured":"US Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified. Accessed March 18, 2020."},{"key":"10.1016\/j.clinthera.2024.12.006_bib0012","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","article-title":"Esketamine nasal spray versus quetiapine for treatment-resistant depression","volume":"389","author":"Reif","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0013","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0014","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2217\/cer-2022-0149","article-title":"Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study","volume":"11","author":"Brendle","year":"2022","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0015","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/JCP.0000000000001465","article-title":"Esketamine nasal spray for the rapid reduction of depressive symptoms in major depressive disorder with acute suicidal ideation or behavior","volume":"41","author":"Canuso","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0016","doi-asserted-by":"crossref","first-page":"21m14090","DOI":"10.4088\/JCP.21m14090","article-title":"Economic burden of commercially insured patients with major depressive disorder and acute suicidal ideation or behavior in the United States","volume":"83","author":"Pilon","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0017","doi-asserted-by":"crossref","first-page":"20m13842","DOI":"10.4088\/JCP.20m13842","article-title":"Mental health care resource utilization and barriers to receiving mental health services among US adults with a major depressive episode and suicidal ideation or behavior with intent","volume":"82","author":"Voelker","year":"2021","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0018","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/13696998.2023.2208993","article-title":"Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States","volume":"26","author":"Zhdanava","year":"2023","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0019","first-page":"1","article-title":"Issues in developing a surveillance case definition for nonfatal suicide attempt and intentional self-harm using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) coded data","volume":"108","author":"Hedegaard","year":"2018","journal-title":"Natl Health Stat Report"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0020","series-title":"SPRAVATO\u00ae (esketamine) [nasal spray prescribing information]","year":"2023"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0021","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4088\/JCP.07m03904","article-title":"The duration of the suicidal process: how much time is left for intervention between consideration and accomplishment of a suicide attempt?","volume":"70","author":"Deisenhammer","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0022","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jamapsychiatry.2018.0768","article-title":"Cost-effectiveness of electroconvulsive therapy vs pharmacotherapy\/psychotherapy for treatment-resistant depression in the United States","volume":"75","author":"Ross","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0023","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1176\/appi.ps.201900625","article-title":"Cost-effectiveness of esketamine nasal spray for patients with treatment-resistant depression in the United States","volume":"71","author":"Ross","year":"2020","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0024","doi-asserted-by":"crossref","first-page":"490","DOI":"10.15585\/mmwr.mm7013e2","article-title":"Symptoms of anxiety or depressive disorder and use of mental health care among adults during the COVID-19 pandemic - United States, August 2020-February 2021","volume":"70","author":"Vahratian","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clinthera.2024.12.006_bib0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamapsychiatry.2020.1730","article-title":"The coronavirus disease 2019 (COVID-19) outbreak and mental health: current risks and recommended actions","volume":"78","author":"Amsalem","year":"2021","journal-title":"JAMA Psychiatry"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824004090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824004090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:49:30Z","timestamp":1778669370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824004090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0149291824004090"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.12.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health Care Resource Use and Medical Costs Among Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine Nasal Spray or Traditional Treatments in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}